Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cancer immunotherapy is one the most effective approaches for treating patients with tumors, as it bolsters the generation and persistence of memory T cells. In preclinical work, it has been reported that adoptively transferred CD4+ and CD8+ lymphocytes that secrete IL-17A (i.e., Th17 and Tc17 cells) regress tumors to a greater extent than IFN-γ+Th1 or Tc1 cells in vivo. Herein, we review the mechanisms underlying how infused Th17 and Tc17 cells regress established malignancies in clinically relevant mouse models of cancer. We also discuss how unique signaling cues—such as co-stimulatory molecules (ICOS and 41BB), cytokines (IL-12 and IL-23) or pharmaceutical reagents (Akt inhibitors, etc.)—can be exploited to bolster the therapeutic potential of IL-17+ lymphocytes with an emphasis on using this knowledge to improve next-generation clinical trials for patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 2×
“1 and described elsewhere [20, 23].”
BackgroundRegulatory T cells: mechanisms of differentiation and function
Josefowicz, S. Z., Lu, L.-F., & Rudensky, A. Y. (2012) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141623 · Cited by 2,866 · cited 1×
“Depending on the cytokines and co-stimulatory/co-inhibitory cues received, CD4+ T cells differentiate into one of several subsets, including Th1, Th2, Th9, Th17, Th22, TFH and regulatory T cells (Treg) [22–24], as depicted in Fig.”
BackgroundCD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606 · cited 1×
“These Th17 markers have not only helped investigators discern them from other subsets [56–59], but helped investigators determine their phenotype and role in various diseases.”
BackgroundGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“Th17 cells require two signals to be activated: The first signal is antigen specific (“signal 1”) and involves TCRdependent recognition of peptide presented by MHC II on antigen-presenting cells and the second signal is co-stimulation (“signal 2”) provided by molecules in the B7-CD28/ TNF receptor superfamily [111, 11…”
BackgroundCouzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051 · cited 1×
“These clinical examples are just some of the reasons why the journal Science Magazine selected cancer immunotherapy as the 2013 “Breakthrough of the Year” [8].”
BackgroundThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“Memory CD8+ T cells with stem cell memory properties, generated in vitro, destroy tumor even more effectively than central memory cells [13].”
BackgroundSelf-citationEffector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828 · cited 1×
“These Th17 markers have not only helped investigators discern them from other subsets [56–59], but helped investigators determine their phenotype and role in various diseases.”
BackgroundAdoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688 · cited 1×
“Using this approach, translational T cell therapy groups have now treated patients with synovial cell sarcoma, cervical cancer, chronic/acute lymphocytic leukemia, multiple myeloma as well as epithelial carcinomas [5, 86–89].”
Background
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Hewitt, S. L., Bai, A., Bailey, D., Ichikawa, K., Zielinski, J., Karp, R., Apte, A., Arnold, K., Zacharek, S. J., Iliou, M. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9143 · Cited by 316
CAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
“According to some studies, Th17 cells can either promote or eliminate tumors depending on the context of the tumor (64, 65).”
BackgroundTargeting the interleukin-17 immune axis for cancer immunotherapy
Vitiello, G. A., & Miller, G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190456 · Cited by 151
“Similar to γδ T cells, Th17 cells exhibit “plasticity,”where the presence or absence of specific cytokines directs differentiation and function (Guéry and Hugues, 2015; Majchrzak et al., 2016).”
Background
Metadata
- Authors
- Majchrzak, K., Nelson, M. H., Bailey, S. R., Bowers, J. S., Yu, X.-Z., Rubinstein, M. P., Himes, R. A., & Paulos, C. M.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2016-01-29
- Volume
- 65
- Issue
- 3
- Pages
- 247-259
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2252371475
- Cited by
- 47
- References
- 25
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. https://app.cochat.ai/papers/10.1007/s00262-016-1797-6
- The paper
- Majchrzak, K., Nelson, M. H., Bailey, S. R., Bowers, J. S., Yu, X.-Z., Rubinstein, M. P., Himes, R. A., & Paulos, C. M. (2016). Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-016-1797-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.